<DOC>
	<DOCNO>NCT01211470</DOCNO>
	<brief_summary>The study investigate safety efficacy PMX-30063 patient treat acute bacterial skin skin-structure infection ( ABSSSI ) .</brief_summary>
	<brief_title>Initial Treatment Acute Bacterial Skin Infections ( ABSSSI ) Caused Staphylococcus Aureus</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<criteria>1 . Have diagnosis ABSSSI S. aureus clinically suspect likely pathogen 2 . Clinical manifestation subject ' ABSSSI must include presence purulent material suitable microbiologic culture , Gram stain examination PCR assay . 3 . The ABSSSI must 75 cm2 great size order subject eligible study . This include primary surround erythema , swell induration . 4 . Superinfected eczema chronic medical condition ( e.g. , atopic dermatitis , hidradentitis suppurativa ) characterize prominent sign inflammation extend period even successful bacterial eradication . ( Subjects ABSSSI involve anatomic location evidence chronic skin condition eligible enrollment . ) 1 . Female patient pregnant , lactate ( breast milk feeding ) , plan pregnancy course study . 2 . History peripheral neuropathy form etiology 3 . Anticipated need prolong antibiotic therapy ( i.e. , &gt; 8 day ) 4 . ABSSSI know suspect caused exclusively Gram negative pathogen anaerobe ( Gram positive Gram negative ) 5 . Diabetic foot infection : define subacute chronic infection ( &gt; 4 week ) ankle patient diabetic neuropathy 6 . Infected burn 7 . Known infection human immunodeficiency virus ( HIV ) CD4 count &lt; 200/mm3 8 . Active hepatitis B hepatitis C receive treatment interferon immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>MRSA</keyword>
	<keyword>ABSSSI</keyword>
	<keyword>Staphylococcus aureus</keyword>
</DOC>